Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers.

Trial Profile

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Dolutegravir; Rifabutin; Rifampicin
  • Indications HIV-1 infections; Mycobacterium avium complex infections; Tuberculosis
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline; ViiV Healthcare
  • Most Recent Events

    • 21 Dec 2011 Actual patient number changed from 26 to 27 as reported by ClinicalTrials.gov.
    • 08 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Dec 2011 Planned end date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top